Literature DB >> 7525912

Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas.

H J Terpe1, R Koopmann, B A Imhof, U Günthert.   

Abstract

Low- and high-grade malignant non-Hodgkin's lymphomas have been investigated by immunohistochemistry for their expression of various integrins and CD44 isoforms. Comparison with the expression patterns obtained in non-malignant adult lymph nodes revealed the following differences: alpha 6 and beta 4 integrins were expressed in several high-grade malignant lymphomas to a lower degree than in both the low-grade malignant lymphomas and the normal lymph nodes; all other integrins (alpha 2, alpha 4, alpha 5, alpha v, beta 1, beta 2, beta 3, and beta 7) did not exhibit significant differences in the expression levels between malignant and non-malignant tissues. The standard isoform of CD44 (CD44s) was highly expressed in all lymphoid tissues. Using CD44 exons-specific monoclonal antibodies, CD44 variant isoforms were not detected in non-malignant lymph nodes and were detected only rarely in low-grade malignant lymphomas. In contrast, high-grade malignant lymphomas expressed several CD44 variant isoforms, which included the products from the variant exons 3v, 6v, and 9v, but not 4v. Specifically, detection of exon 3v and 6v products indicates a more aggressive phenotype.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525912     DOI: 10.1002/path.1711740205

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

Review 1.  The clinical significance of malfunction of the CD44 locus in malignancy.

Authors:  D Tarin; J Bolodeoku; S J Hatfill; T Sugino; A C Woodman; K Yoshida
Journal:  J Neurooncol       Date:  1995-12       Impact factor: 4.130

Review 2.  CD44 and the adhesion of neoplastic cells.

Authors:  Z Rudzki; S Jothy
Journal:  Mol Pathol       Date:  1997-04

3.  CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma.

Authors:  N Guriec; L Marcellin; B Gairard; H Caldéroli; A Wilk; R Renaud; J P Bergerat; F Oberling
Journal:  Clin Exp Metastasis       Date:  1996-10       Impact factor: 5.150

4.  Progressive loss of CD44 gene expression in invasive bladder cancer.

Authors:  T Sugino; H Gorham; K Yoshida; J Bolodeoku; V Nargund; D Cranston; S Goodison; D Tarin
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

5.  Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours.

Authors:  B Terris; J F Fléjou; S Dubois; P Ruszniewski; J Y Scoazec; J Belghiti; F Potet; P Bernades; M Mignon; D Hénin
Journal:  Clin Mol Pathol       Date:  1996-08

6.  Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases.

Authors:  A Tzankov; A-C Pehrs; A Zimpfer; S Ascani; A Lugli; S Pileri; S Dirnhofer
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

7.  The expression of variant CD44 in nasopharyngeal carcinoma is unrelated to expression of LMP-1.

Authors:  L Brooks; G Niedobitek; A Agathanggelou; P J Farrell
Journal:  Am J Pathol       Date:  1995-05       Impact factor: 4.307

8.  Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma.

Authors:  Sonja Eberth; Björn Schneider; Andreas Rosenwald; Elena M Hartmann; Julia Romani; Margarete Zaborski; Reiner Siebert; Hans G Drexler; Hilmar Quentmeier
Journal:  BMC Cancer       Date:  2010-09-29       Impact factor: 4.430

Review 9.  Prognostic significance of CD44V6 expression in osteosarcoma: a meta-analysis.

Authors:  Yunyuan Zhang; Chunming Ding; Jing Wang; Guirong Sun; Yongxian Cao; Longqiang Xu; Lan Zhou; Xian Chen
Journal:  J Orthop Surg Res       Date:  2015-12-23       Impact factor: 2.359

10.  Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma.

Authors:  S-K Leivonen; M Taskinen; A Cervera; M-L Karjalainen-Lindsberg; J Delabie; H Holte; R Lehtonen; S Hautaniemi; S Leppä
Journal:  Blood Cancer J       Date:  2017-08-25       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.